CMS Continues to Block People Living with Alzheimer's from Access to FDA-Approved Treatments
Despite significant new evidence published since the release of its decision, CMS has denied the Alzheimer’s Association’s request to change its policy. CMS covers all FDA-approved drugs except for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease.
Alzheimer’s disease is one of the most critical public health issues in America. That’s why the Alzheimer’s Impact Movement (AIM), the Alzheimer’s Association and our advocates are unrelenting. We fight to support Alzheimer's and dementia research funding and advance bipartisan legislation that will have a positive and meaningful impact on people living with Alzheimer's and their caregivers today and in the future.
With the support of volunteer advocates and bipartisan congressional champions we’re making an impact. Help us persuade policymakers to make Alzheimer’s a national priority.
We advocate for the more than 6 million Americans living with Alzheimer’s, a progressive and fatal brain disease.
We’ve increased the federal investment in Alzheimer’s and dementia research funding more than seven-fold in the last decade.
More than 11 million Americans provide unpaid care for people living with Alzheimer’s or other dementias.
Comprehensive Care for Alzheimer’s Act Washington, D.C., March 3, 2023 — The Alzheimer’s Association and the Alzheimer’s Impact Movement (AIM) are proud to support the bipartisan Comprehensive Care...
Alzheimer’s Policy in the States
Across the nation AIM advocates are working to advance public policies to improve the lives of individuals and families impacted by Alzheimer’s and all other dementia. Learn about Alzheimer’s policies and advocacy in your state.